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Abstract: To develop proper drug formulations and to optimize the delivery of their active ingredients
through the dermal barrier, the Franz diffusion cell system is the most widely used in vitro/ex vivo
technique. However, different providers and manufacturers make various types of this equipment
(horizontal, vertical, static, flow-through, smaller and larger chambers, etc.) with high variability and
not fully comparable and consistent data. Furthermore, a high amount of test drug formulations and
large size of diffusion skin surface and membranes are important requirements for the application
of these methods. The aim of our study was to develop a novel Microfluidic Diffusion Chamber
device and compare it with the traditional techniques. Here the design, fabrication, and a pilot testing
of a microfluidic skin-on-a chip device are described. Based on this chip, further developments
can also be implemented for industrial purposes to assist the characterization and optimization of
drug formulations, dermal pharmacokinetics, and pharmacodynamic studies. The advantages of
our device, beside the low costs, are the small drug and skin consumption, low sample volumes,
dynamic arrangement with continuous flow mimicking the dermal circulation, as well as rapid and
reproducible results.
Keywords: skin-on-a-chip; microfluidics; Franz diffusion cell; transdermal microdialysis; drug delivery
1. Introduction
For testing drug absorption across the dermal barrier there are in vitro, ex vivo, and in vivo techniques
in the toolbox of pharmaceutical researchers. For in vitro testing, different types of membranes are used
and mounted in a gold-standard system of horizontal or vertical Franz diffusion cells as a first approach [1].
Usually, polymeric membranes [2,3] are applied for release testing. According to the Food and Drug
Administration (FDA) SUPAC-SS (Scale-Up and Post Approval Change Semisolids) (May 1997), inert and
synthetic membranes such as polysulfone and cellulose acetate/nitrate mixed ester can be used. Generally,
hydrophilic polymeric membranes with a pore size of 0.45 µm are used. Based on our previous results, this
pore size is equivalent to the porosity of the 10-tape-stripped rat skin [4]. The next step in the complexity
of the drug release and penetration testing is the application of different skin preparations from animals
and humans in Franz cells. The small animal (such as rat, mouse, and rabbit) skins [4] have traditionally
been used in studies to predict human tissue permeability as they are usually inexpensive to purchase
and maintain. Those tissues are thinner than human skin and have different morphologies resulting in
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higher compound permeabilities. Large animal skins (such as monkey, dog, and pig) [5–7] have also been
used extensively but are expensive to purchase, especially in the cases of monkeys and dogs. Pig and
monkey soft tissue is very similar to human soft tissue in terms of morphology and function; therefore,
they are widely used as a substitute for human skin. The ex vivo human tissue [8] is difficult to obtain
in sufficient quantities from normal, healthy subjects to perform permeability experiments with large
enough sample sizes for statistical analysis. Many laboratories use, therefore, human cadaver skin [3,9]
obtained from accredited tissue banks. However, ethical and legal concerns may arise when obtaining
human tissue biopsies and surgical specimens.
To obtain predictive and real-time results considering the kinetics and dynamics of drug delivery
into the skin, in vivo transdermal microdialysis can be a good choice in different species. Both the ex
vivo and the in vivo techniques have strengths and weaknesses. The strengths are that they are widely
used in the drug development and pharmaceutical research and provide reliable and reproducible
results. The disadvantages are the robustness, the high tissue, test compound and formulation needs,
and the high costs. The usual size of adsorption surface in Franz diffusion cells is ~1.3–1.8 cm2/chamber
and 6 parallels are simultaneously studied. To set up the instrument, several animals need to be
sacrificed or human tissue should be purchased from plastic surgery or other sources. For use of
human tissue ethical permissions are needed. To overcome these difficulties the miniaturization of
Franz diffusion cell systems looks a promising option.
Skin-on-chip devices offer innovative and state-of-the-art platforms essential to overcome the
above-mentioned limitations of Franz diffusion cells [10]. In some studies, organotypic cultures are
cultivated in the chips to mimic human skin and the transepithelial electrical resistance (TEER) is
detected [11–13] for characterization the diffusion properties. The tissue vascularization can also be
considered in the preparation of skin cell containing co-cultures [14]. The impact of tissue engineering,
biomaterials, and microfluidic platforms on the development of skin grafts and biomimetic in vitro
skin models are reviewed by Mohammadi and co-workers [15] and these techniques can also be used
for the development of novel skin disease platforms for drug-screening assays.
In our laboratory, a novel, temperature-controlled microfluidic device has been designed and fabricated
for testing drug penetration through the skin. To evaluate its function under real conditions, a hydrophilic
model drug, caffeine, has been tested in a Vaseline-based cream formulation. The drug penetration has been
measured in native and sensitized mouse and rat skin in the skin-on-a chip device and for comparison and
evaluation Franz diffusion cell and transdermal microdialysis experiments were also performed.
2. Materials and Methods
2.1. Materials and Solutions
Both for in vivo and for ex vivo experiments, peripheral perfusion fluid (PPF) was used as a
physiological solution. Chemical composition of PPF: 147 mM NaCl, 4 mM KCl, and 2.3 mM CaCl2·2
H2O. All substances were purchased from: Sigma-Hungary Kft, Budapest, Hungary.
2.2. Cream Formulation
A cream containing 2% of caffeine was used in all studies. Caffeine was acquired from
Sigma-Hungary Kft (Budapest, Hungary).
The test formulation of caffeine was compounded according to the following description: 2 g of caffeine
was dispersed with 4.1 g of liquid paraffin (Ph. Hg.) in a mortar with pestle, then 47 g of white soft paraffin
ointment (containing polysorbate 60 (Ph. Hg.) 4 m/m%, liquid paraffin 8 m/m%, white soft paraffin 26 m/m%,
cetostearyl alcohol (Ph. Hg.) 12 m/m%, propylene glycol 10 m/m% and purified water 40 m/m%), 10 g
propylene glycol (Ph. Hg.), and 36.9 g of 0.21 m/m% citric acid aqueous solution were added.
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2.3. Franz Diffusion Cell Study
The Franz diffusion cell system (Hanson, ABL&E-JASCO Hungary Kft, Budapest, Hungary) used
in the study is composed of six sampling units with vertical arrangement. Every cell has a donor and a
receptor chamber, the latter contains PPF, its capacity is 7.5 mL. The test skin preparation, which has the
test drug in proper quantity (0.5 g) on its external surface was placed between the two compartments.
Attention was paid to the airless placement of the skin.
The drug penetrates through the skin into the PPF. In the acceptor unit a helical mixer is applied
to generate continuous stirring, which can stimulate the drug release and ensures the homogeneity of
the fluid. The release medium was mixed on 320 rpm and heated at 32 ◦C.
2.3.1. Skin Preparation
Male Wistar rats (ToxiCoop, Budapest, Hungary) weighing 300–340 g and male NMRI mice
(ToxiCoop, Budapest, Hungary) of 30–40 g were used for the experiments. Chloralhydrate (purchased
from Sigma-Hungary Kft, Budapest, Hungary) was applied as anesthetics in a dose of 400 mg/kg i.p.
in rats and 450 mg/kg i.p. in case of mice.
Initially, the hair on the abdominal skin was removed; the skin was shaved off and wiped dry. An
emphasis was put on the tape-stripping method. The goal was to study the penetration blocking effect
of the stratum corneum layer, therefore one half of the skin preparations was tape-stripped 10 times.
The process resulted in the partial removal of dead keratinocytes. The skin surface treated with caffeine
cream was 1.766 cm2, accordingly the dose of applied caffeine was 6.0 mg/cm2.
The skin preparations were stored in PPF on room temperature until the initiation of ex vivo
experiments. The Franz diffusion cell studies were started within 12 h after the surgery. At the
beginning of the experiments the preparations were placed on the cells. The stratum corneum layer
was facing the donor chamber, contacting the test drug and the dermal-subcutaneous surface was
contacting the PPF on the acceptor compartment’s side.
2.3.2. Sample Collection
Samples have been collected from the receptor chamber through a needle in every 30 min for six
hours. Peripheral Perfusion Fluid 0.5 mL of volume was injected in the receptor compartment through
a replacement port at every sampling occasion. That resulted in the outflow of 0.5 mL sample through
the sampling needle.
2.4. Transdermal Microdialysis Study
Microdialysis is an in vivo sampling technique for monitoring the biochemical changes of the
extracellular milieu in different tissues with minimal tissue damage [16]. In vivo transdermal microdialysis
was performed according to our previous paper [17]. Briefly, one or two microdialysis probes with a
semipermeable membrane were introduced into the dermal layer of the skin, and were continuously
perfused with the peripheral perfusion fluid (PPF). Samples were collected into vials and analyzed.
2.4.1. Animals
Adult male Wistar rats (ToxiCoop Zrt., Budapest, Hungary), weighing 280 to 330 g, and adult male
NMRI mice (ToxiCoop Zrt., Budapest, Hungary) weighing 30 to 35 g, housed in animal room (12 h light/dark
periods, 22 ± 3 ◦C temperature, 50 ± 20% humidity) fed with commercial laboratory chow and tap water
ad libitum, were used. All experiments in this study were conform to the guidelines of the Association for
Assessment and Accreditation of Laboratory Animal Care International’s expectations for animal use, and
were licensed by the Directorate for the Safety of the Food Chain and Animal Health, Budapest, and Pest
County Agricultural Administrative Authority, Hungary (PE/EA/672-6/2016, 8 April 2016).
Pharmaceutics 2019, 11, 445 4 of 14
2.4.2. Surgery and Performance of Microdialysis Experiments
Preparation of both rat and mouse abdominal skin surface was performed in the in vivo laboratory,
on the day before the microdialysis experiments. Animals were anaesthetized with chloral hydrate
(Sigma-Aldrich, Steinheim, Germany), 400 mg/kg i.p. for rats, and 450 mg/kg i.p. for mice. The abdominal
skin surface was shaved off with an electric shaver, then epilated by an epilator cream (ISANA® cream
from Rossmann, Burgwedel, Germany), after that the animals returned to their cages.
Next day, on the day of transdermal microdialysis experiment, animals were reanesthetized
intraperitoneally with chloral hydrate and fixed in supine position on a heating pad to keep their
body temperature at a constant of 37 ◦C during the in vivo experiment. The abdominal skin was
wiped dry. Rats and mice were randomly divided into two groups; the skin of five rats and five mice
were sensitized 10 times (10 TS) by tape-stripping with leucoplast (BSN Medical GmbH, Hamburg,
Germany) to remove the dead cell layer of stratum corneum; the skin of another five rats and five mice
were not tape-stripped (0 TS).
After the sensitization, the microdialysis probes were introduced through a guide needle (18G)
into the dermal tissue. The guide needle was then withdrawn, and the probe membrane stayed in the
dermal tissue. In rats two probes (MAB 11.8.10, Microbiotech, Stockholm, Sweden) were introduced,
in parallel, 20 mm distance to each other; in mice one single microdialysis probe (MAB 7.8.10, Microbiotech,
Stockholm, Sweden) was inserted (Figure 1). Probes were then fixed carefully with a tape (Omnisilk,
Hartmann, Germany). The position of the probes was verified in a pilot experiment by ultrasound
scanning. The microdialysis probes were continuously perfused with artificial PPF at 1 µL/min flow rate.
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Figure 1. Implantation of microdialysis probes and placement of drug-containing patches in a
representative mouse (left) and rat (right) in transdermal microdialysis experiments.
Thereafter, transdermal patches (Curatest®F, Lohmann Rauscher GmbH, Rengsdorf, Germany),
containing 50 mg of 2% caffeine crea formulation were placed on the skin, exactly above the position
of microdialysis probe membrane.
2.4.3. Sample Collection
Dialysate samples were collected into 300 µL collection vials every 30 min. One sample collection
was performed before the placement of the patches (for equilibration), dialysis sampling was then
maintained for a total of 4 h in mice, and 5 h in rats. Collected dialysate samples were immediately
placed on dry ice, and samples were stored at −80 ◦C in a freezer until bioanalysis.
2.5. Skin-on-a-Chip Diffusion Cell Study
2.5.1. Design and Fabrication of the Device
We have developed a Microfluidic Diffusion Chamber (MDC) (Figure 2A) for in vitro/ex vivo
monitoring of transdermal delivery of topical drugs. In the current study caffeine was used as a
hydrophilic model drug. The microfluidic channel system is fabricated by polymer-based techniques,
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which has been surrounded by poly(methyl methacrylate) (PMMA) and polylactic acid (PLA) components
(Sunlu, Zhuhai, China) using Crafbot 2 (Creafbot Unique, Budapest, Hungary) and a FFF (Fused Filament
Fabrication) type 3D printer. The MDC device had a temperature-controlled module, which was devoted
to set the process at constant temperature (Figure 2B). The embedded heating element was automatically
regulated by Arduino UNO (Arduino, Somerville, MA, USA) via a built in proportional–integral–derivative
(PID) controller function. The device is made of three functional elements: on top is a donor compartment
where the examined cream is poured, in the middle is an integrated skin sample (or alternatively a
membrane), and the bottom is the receptor compartment. A heating foil was placed between the
bottom acrylic glass and the bottom polydimethylsiloxane (PDMS) layer exactly under the receptor cell
to maximize the heat transfer and minimize the power consumption. The donor compartment has a
truncated cone shape, where top surface radius is 18 mm, the base radius is 8 mm and the height is 6 mm,
and this fixes the skin sample onto the microfluidic structure. The receptor compartment is implemented
into the microfluidic channel system, which is made of PDMS (SYLGARD™ 184 Silicone Elastomer Kit,
Dow Consumer Solutions, Los Angeles, CA, USA). The microfluidic channel is 1.4 mm wide, 1 mm high,
and 60 mm long, and has one inlet and one outlet. It connects to the receptor compartment with 5 mm
diameter in the middle. PDMS liquid monomer and its treating agent are mixed at a 10:1 ratio, and
incubated at 70 ◦C for 2 h. The polymerized PDMS is manufactured into the proper shape and punched
through for 1 mm diameter of inlet, 1 mm diameter of outlet and 5 mm diameter of reservoir (receptor
chamber). The temperature was transferred by flexible electric polyimide film heater and controlled by a
thermostat (TSM 125 Temperature controller, H-Tronic, Hischau, Germany).
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Figure 2. Exploded schematic view of the Microfluidic Diffusion Chamber (MDC) (A). Left:
Layer-by-layer view of the device. Right: Cross sectional view of the device. Temperature-controlled
skin-on-a chip device (MDC) (B). Left: The bottom side of the chip with the circular thin film heater
and thermistor. Right: The temperature control measurement with a thermo-camera.
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2.5.2. Lab-on-a-Chip Sample Collection
The PPF solution has been loaded into a 5 mL syringe. The air bubbles have been removed
previously from the syringe and from the connected Teflon tubing before the load. The backpressure
has been generated by a programmable syringe pump (NE-1000, New Era, Farmingdale, NY, USA).
The flow rate has been set at along the entire measurement. The PPF solution has been forced through
the microfluidic system, filled the receptor chamber and left on the outlet into collection vials (Figure 3).
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Figure 3. The performance of a microfluidic diffusion chamber (MDC) experiment. Left: The set-up of
the microfluidic system with a syringe pump and the chip. Right: The position of the sample collection
vial in the 3D printed measurement bench of the microfluidic device.
2.6. Bioanalysis
2.6.1. Spectroscopy-Franz Diffusion Cell Samples
The caffeine content of the Franz cell samples was measured with a Shimadzu UV-visible
spectrophotometer UV-1650PC. The collected samples were dil t i 1.5 mL PPF, thereby th
cuvettes were fill d with 2 mL of diluted sample. The concentration was measured against th buffer.
The absorbance was accepted between 0.1 and 1 1, otherwise the samples were further diluted.
The absorption maximum of the caffei e was detected at 273 nm. From these values, caffeine
concentrations were calculated accordi g to the Lambert-Beer law:
E = log(I/I0) = εcL,
where E means the absorbance, I0 = light intensity in front of the cuvette, I = light intensity behind the
cuvette, ε = molar extinction coefficient, c = concentration and L = thickness of the cuvette.
2.6.2. LC-MS/MS-Dialysate and Chip Samples
The quantitative LC-MS/MS analysis was done in positive electrospray ionization (ESI) mode
on Thermo Q Exactive Focus orbital mass spectrometer coupled with Thermo Dionex Ultimate
3000 UHPLC system (UNICAM Hungary Ltd., Budapest, Hungary). The high performance liquid
chromatography (HPLC) column was Phenomenex Kinetex XB-C18, 2.1× 50 mm column (Gen-Lab Ltd.,
Budapest, Hungary) used in isocratic chromatographic conditions where the eluent was containing
8% acetonitrile and 0.1% formic acid in water. The analysis time was 1.5 min. The mass spectrometer
operated in PRM (Parallel Reaction Monitoring) mode where m/z: 195.0876 parent ion was fragmented
at NCE: 55 (scan range: 50.0000–220.0000 m/z). The m/z: 138.06606 ion was used as a quantifier ion.
The ESI source parameters were the following: Spray voltage (V): 3500, capillary temperature (◦C): 256,
probe heater temperature (◦C): 413, sheath gas: 48, auxiliary gas: 11, sweep gas: 2, all gas flow rates
are in arbitrary units. A typical chromatogram of caffeine is presented in Figure 4. Five calibration
levels were used by the quantitation in 0.08–50 µM range with 1:5 dilution pattern (Figure 5).
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2.7. Histology
One-one representative skin preparation was taken from a native mouse, a native rat, a sensitized
(10 tape-stripping) mouse and a sensitized (10 tape-stripping) rat. The skin samples were placed
into 10% formaldehyde and paraffin, and embedded. To analyze the cellular changes caused by the
sensitization process Hematoxylin-Eosin staining was used.
3. Results
3.1. Franz Diffusion Cell Studies
In the ex vivo Franz cell experiments non-sensitized and sensitized mouse and rat skins were
compared for caffeine permeability (F gure 6). Both i rats and in mice s atistically ignificant differences
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have been detected after the 10-tape-stripping (10 TS) in the caffeine absorption compared to the
respective controls (0 TS). The degree of caffeine penetration correlated closely with the number of
sensitizations in rats. As the permeability of the mouse skin was higher in non-sensitized animals
than that of in rats (AUCM0TS = 127,466 ± 63,424 vs. AUCR0TS = 58,823 ± 3933 µg/mL·min) it is
not surprising that the effect of the 10 tape-stripping was also more pregnant in mice than in rats
(AUCM10TS = 540,196 ± 102,528 vs. AUCR10TS = 221,358 ± 10,394 µg/mL·min).Pharmaceutics 2018, 10, x 9 of 15 
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3.2. Transdermal Microdialysis Study
Caffeine absorption was also compared in vivo in mice and rats with and without skin sensitization
(Figure 7). The free levels of caffeine in the dermis showed a peak in both species at 60 min after the
placement of caffeine cream containing patches on the skin. However, theCmax values were about 8-fold
higher in mice than in rats. The elimination dynamics of the drug showed faster characteristics in the
mouse than in the rat. The in vivo data are in line with the ex vivo Franz diffusion cell results concerning
the degree and the statistical strength (significance) of the effect of tape-stripping and regarding the
difference between the two species (AUCM0TS = 452 ± 202 vs. AUCM10TS = 77,167 ± 34,510 µg/mL·min
and AUCR0TS = 741 ± 234 vs. AUCR10TS = 18,222 ± 5762 µg/mL·min).
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3.3. Skin-on-a-Chip Diffusion Cell Study
Caffeine absorption was measured also in Microfluidic Diffusion Chamber (MDC) (Figure 8).
The degree of absorption was approximately 50% of that measured by Franz cell. However, it is
important to mention that the caffeine content of Franz cell samples was determined by spectroscopy,
while the microfluidic samples were analyzed by LC-MS/MS. Based on these methodological differences
the results can only be evaluated separately. In the chip, similarly to microdialysis data, the native rat
skin was more permeable than mouse skin (AUCM0TS = 7902 ± 1402 vs. AUCR0TS = 15,900 µg/mL·min),
but the sensitization resulted in higher increase in caffeine absorption in mouse skin than in rat skin
(AUCM10TS = 180,621 ± 25,217 and AUCR10TS = 75,588 ± 7389 µg/mL·min).
3.4. Histology
Figure 9 shows that the tape-stripping more or less removed the external surface of stratum
corneum in the sensitized skins (arrows in Figure 9C,D).
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Figure 9. Histological structure of native and sensitized rat and mouse abdominal skin preparations 
(Hematoxylin-Eosin staining). (A): native rat skin (0 tape-stripping), (B): native mouse skin (0 tape-
stripping), (C): sensitized (10 tape-strippings) rat skin, (D): sensitized (10 tape-strippings) mouse skin. 
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Figure 9. Histological structure of native and sensitized rat and mouse abdominal skin preparations
(Hematoxylin-Eosin staining). (A): native rat skin (0 tape-stripping), (B): native mouse skin (0
tape-stripping), (C): sensitized (10 tape-strippings) rat skin, (D): sensitized (10 tape-strippings) mouse skin.
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4. Discussion and Conclusions
Many compounds are applied on the skin either deliberately or accidentally, with either beneficial
or deleterious outcomes. The dermal absorption assessment can be important for evaluating:
(a) local effects in dermatology (e.g., corticosteroids for dermatitis); (b) delivery through the skin
seeking a systemic effect (e.g., nicotine patches, hormonal drug patches, etc.); (c) surface effects (e.g.,
sunscreens, cosmetics, and anti-infectives) [18,19]; (d) targeting of deeper tissues (e.g., non-steroidal
anti-inflammatory agents) [20–29]; and (e) unwanted absorption (e.g., solvents in the workplace,
pesticides or allergens) [19,30,31].
Removal of the outermost skin layer of stratum corneum by tape-stripping has become a common
practice in recent decades for preclinical testing [19,32,33]. The determination of the kinetics and
penetration depth of different drugs can be facilitated using the practically non-invasive method of
tape-stripping with adhesive tape [34,35]. Tape-stripping makes easier the evaluation of bioequivalence
of topical dermatological dosage forms and makes possible to reach detectable concentrations of
the drugs in the dermis and subcutis in preclinical animal models [4,36]. Therefore, in our study,
tape-stripped and non-stripped skins were studied in parallel for permeability.
For the investigation of skin penetration of drugs, unwanted chemicals, and cosmetics, new
techniques are needed which can use the knowledge gained from the previous in vitro, ex vivo, and
in vivo studies, but require fewer biomaterials, skins, skin equivalents, and test compounds. For this
reason, the microfluidic environment looks an optimal approach to reach our goal: to miniaturize
the diffusion set-up. After some previous studies in cell culture platforms [12,37,38] to realize this
approach, our laboratory produced a device to fulfill the requirements of the pharmaceutical and
cosmetic industry to make an economical and reliable drug-screening platform. The parallelization,
automation, and further developments according to the requirements of the researchers and end users
are in progress.
In the current study, the first biological evaluation of a novel MDC device is presented using the
most easily available skin preparations from rodents. This assay can be considered to be a first level of
ex vivo screening for topical drugs. The investigation of drugs can be further continued by artificial
skin equivalents or even human skins.
In comparison with data gained from traditional Franz cell experiments, our MDC device seems
to provide similar information about the characteristics, degree, and speed of absorption of the test
drug (caffeine) through the dermal barrier. Although the Cmax values show an approximately two-
fold difference between the Franz cell and the microfluidic data, this variability might have different
backgrounds. One possible explanation is the different bioanalytical methods used (as mentioned
earlier), and the other possibility is the material of the acceptor module of the microfluidic chamber
which was made of PDMS. This polymer has a strong absorptive property for small molecules, mainly
for lipophilic compounds [39,40]. Although caffeine is a very hydrophilic molecule (logP = −0.79), it
can be assumed that there is some non-specific interaction with the chamber’s material. Therefore,
the next step in the validation of the device will be the application of bovine serum albumin (BSA) in
the perfusion fluid to reduce the possible non-specific binding to PDMS. The other option is to change
the material of the acceptor panel e.g., to glass or other less absorptive material.
Recently, several experiments have been performed worldwide to use skin equivalents in the
drug penetration experiments [41–45]. To develop more sophisticated skin substituents and optimize
them for possible dermatological, pharmaceutical, or surgical purposes, our device would provide a
reliable, low-cost testing platform.
In conclusion, in this paper a new skin-on-a chip microfluidic device has been presented. It
was tested and compared with traditional drug penetration assays and optimized for pharmaceutical
purposes. It can be further developed for special use, e.g., for testing cell culture platforms, artificial
skins, or other tissues such as oral or nasal mucosa, or eye formulations. By further engineering,
the parallelization of the device can also be implemented.
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